Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Buy" from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $54.20.

Several equities research analysts have recently issued reports on the stock. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a research note on Thursday, November 14th. The Goldman Sachs Group raised their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, November 15th. Finally, William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Lord Abbett & CO. LLC raised its stake in shares of Tarsus Pharmaceuticals by 28.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company's stock valued at $19,565,000 after purchasing an additional 131,636 shares during the period. Exome Asset Management LLC purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter valued at about $1,500,000. Franklin Resources Inc. grew its holdings in Tarsus Pharmaceuticals by 9.3% during the 3rd quarter. Franklin Resources Inc. now owns 12,164 shares of the company's stock valued at $444,000 after buying an additional 1,033 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company's stock valued at $27,494,000 after buying an additional 62,555 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Tarsus Pharmaceuticals by 345.9% in the third quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after buying an additional 76,538 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Performance

TARS traded down $0.37 during trading on Tuesday, hitting $54.04. 128,793 shares of the company traded hands, compared to its average volume of 709,549. The firm has a market cap of $2.07 billion, a P/E ratio of -14.18 and a beta of 1.04. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a one year low of $18.99 and a one year high of $56.77. The stock's fifty day moving average is $46.87 and its 200 day moving average is $35.20.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.